Onco Wiki / Droga

Rituximab

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDDRUG-RITUXIMAB
TipoFármaco
Alegais
MabTheraRiabni (biosimilar)RituxanoRuxiência (biosimilar)Truxima (biosimilar)Ритуксимаб
Estadoreviewed 2026-04-26 | pending_clinical_signoff
DoençasDIS-B-ALL DIS-BURKITT DIS-CLL DIS-DLBCL-NOS DIS-FL DIS-HCL DIS-HCV-MZL DIS-HGBL-DH DIS-MCL DIS-NLPBL DIS-NODAL-MZL DIS-PCNSL DIS-PMBCL DIS-PTLD DIS-SPLENIC-MZL DIS-T-ALL DIS-WM
FontesSRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025

Fatos sobre as drogas

Classemonoclonal_antibody — anti-CD20 chimeric IgG1κ
MecanismoChimeric (mouse-human) monoclonal antibody binding the CD20 antigen on B lymphocytes (pre-B through mature B; sparing pro-B and plasma cells). Depletes CD20+ B cells via three mechanisms: complement-dependent cytotoxicity (CDC, dominant in CLL), antibody-dependent cellular cytotoxicity (ADCC, dominant in lymphoma), and direct apoptosis via CD20 cross-linking. Recovery of normal B cells takes 6-12 months after the last dose.
Dose típicaR-CHOP / R-CVP / R-Bendamustine (DLBCL, FL): 375 mg/m² IV day 1 of each 21- or 28-day cycle × 6-8 cycles. R-monotherapy / FL maintenance: 375 mg/m² IV every 8-12 weeks × 2 years (PRIMA / RESORT schedules). CLL (R-FC, R-Ben): 375 mg/m² IV cycle 1 day 1, then 500 mg/m² IV day 1 cycles 2-6. SC formulation (FL, DLBCL): 1400 mg fixed-dose SC over ~5 minutes from cycle 2 onward (after first IV dose for tolerability).
Ucrânia registadaVerdade
NSZU reembolsadoVerdade
Ucrânia verificada pela última vez2026-04-27

Avisos

Notas

Foundation anti-CD20 therapy in B-cell lymphomas. Premedication (acetaminophen + diphenhydramine ± methylprednisolone) before each infusion; first-dose infusion rate escalation per protocol (50 mg/h start, doubled q30min to max 400 mg/h). HBV screening (HBsAg + anti-HBc + anti-HBs) is mandatory before first dose; entecavir or tenofovir prophylaxis throughout therapy and ≥12 months post for any HBV-positive serology. SC formulation reduces administration time from 4-6 h to 5-7 minutes and is preferred from cycle 2 onward in FL / DLBCL. For HCV-MZL, reserved for cases not responding to antiviral therapy alone, or aggressive phenotype where immediate cytoreduction is indicated. Biosimilars are clinically interchangeable in UA per НСЗУ guidance.

Usado por

Contraindications

Esquema terapêutico